National Cancer Institute; Notice of Meeting, 60887 [2013-23961]

Download as PDF Federal Register / Vol. 78, No. 191 / Wednesday, October 2, 2013 / Notices Dated: September 25, 2013. Glenda J. Conroy, Executive Officer (OM Director), NIDA, NIH. [FR Doc. 2013–23972 Filed 10–1–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: September 26, 2013. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health National Cancer Institute; Notice of Meeting [FR Doc. 2013–23961 Filed 10–1–13; 8:45 am] BILLING CODE 4140–01–P tkelley on DSK3SPTVN1PROD with NOTICES Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Board of Scientific Advisors. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: National Cancer Institute Board of Scientific Advisors. Date: November 7, 2013. Time: 9:00 a.m. to 5:00 p.m. Agenda: Director’s Report: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentations, Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations. Place: National Institutes of Health, Building 31, C-Wing, 6th Floor, Conf. Rm. 10, 31 Center Drive, Bethesda, MD 20892. Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Rm. 7W444, Bethesda, MD 20892, 240–276–6340, grayp@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: http:// deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; VerDate Mar<15>2010 17:48 Oct 01, 2013 Jkt 232001 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) DEPARTMENT OF HOMELAND SECURITY Expressions of Interest (EOI) for Chemical Defense Demonstration Projects Office of Health Affairs, DHS. Notice of Expression of Interest. AGENCY: ACTION: The Chemical Defense Program (CDP), under the Department of Homeland Security Office of Health Affairs (OHA), is seeking Expressions of Interest (EOI) from state, local, tribal, and territorial (SLTT) government agencies to participate in a chemical defense demonstration project relative to a specific venue (e.g., indoor sports stadium, outdoor port facility, convention center). These projects will assist communities in enhancing their preparedness to respond effectively and quickly to a catastrophic chemical event. Using the DHS Form 10088 (9/12) posted on https://www.dhs.gov/ publication/eoi-form-cdpdemonstration-project, interested SLTT governmental agencies must submit the completed and signed form to the DHS OHA CDP. DATES: Submit the completed and signed DHS Form 10088 (9/12), either electronically or in hard copy, no later than 45 days from the date of the Federal Register Notice. ADDRESSES: Submissions of DHS Form 10088 (9/12) shall go to the following: Hardcopy signed original document to Captain Joselito Ignacio Deputy Program Director, Chemical Defense Program Department of Homeland Security/ Office of Health Affairs, 245 Murray Lane SW., Mail Stop: 0315 Washington, DC 20528; or Electronically to Joselito.Ignacio@hq.dhs.gov. FOR FURTHER INFORMATION CONTACT: CAPTAIN JOSELITO IGNACIO, 202– 254–5738 OR joselito.ignacio@ hq.dhs.gov. SUMMARY: The demonstration projects are based on SUPPLEMENTARY INFORMATION: PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 60887 appropriations found in Public Law 112–74 (Consolidated Appropriations Act, 2012) and Public Law 133–6 (‘‘The Consolidated and Further Continuing Appropriations Act, 2013’’), which call for the Chemical Defense Program of DHS OHA to conduct a competitive selection of locations and venues to participate in chemical detection demonstration projects. The DHS OHA CDP will initiate, fund and manage the demonstration projects, but in close coordination with the selected SLTT government agencies and venue operators. The demonstration project will result in, among other things: (a) A review of current community preparedness capabilities as well as gaps protecting from and responding to a catastrophic chemical incident; (b) community and venue-specific risk assessments, based on likely scenarios, to provide information on chemical threats; (c) technology alignment to include review of existing or intended detect-to-warn or detect-to-treat capabilities in communities; (d) optimizing the communities’ response system through decision analysis and the development of a concept of operations plan that defines common mission, roles, responsibilities and key actions necessary for responding to these events; and (e) exercise evaluation using the Homeland Security Exercise and Evaluation Program (HSEEP) process. Through successful completion of these demonstration projects, the selected communities will have enhanced preparedness of their emergency management, first responder, and first receiver groups with the knowledge, skills and tools to act swiftly and competently in protecting lives and restoring peace of mind in response to a catastrophic chemical incident. As stated, DHS will conduct a competitive selection. A DHS selection panel, led by the DHS OHA CDP, will carefully review the completed and signed DHS Form 10088 (9/12) and rate each submission using weighted criteria on the basis of (a) chemical threat risk (which the DHS Chemical Terrorism Risk Assessments and SLTT government agencies’ input will inform); (b) community interest to host a demonstration project; and (c) reasons given for desiring a demonstration project hosted in this community and specific venue. Numerically sequenced from high to low values, top tiered communities are then selected to have these projects conducted in their locations. All communities will receive notification of the selection results. Once selected, DHS OHA CDP will enter E:\FR\FM\02OCN1.SGM 02OCN1

Agencies

[Federal Register Volume 78, Number 191 (Wednesday, October 2, 2013)]
[Notices]
[Page 60887]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23961]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
National Cancer Institute Board of Scientific Advisors.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: National Cancer Institute Board of Scientific 
Advisors.
    Date: November 7, 2013.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: Director's Report: Ongoing and New Business; Reports of 
Program Review Group(s); and Budget Presentations, Reports of 
Special Initiatives; RFA and RFP Concept Reviews; and Scientific 
Presentations.
    Place: National Institutes of Health, Building 31, C-Wing, 6th 
Floor, Conf. Rm. 10, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, 
Division of Extramural Activities, National Cancer Institute--Shady 
Grove, National Institutes of Health, 9609 Medical Center Drive, 7th 
Floor, Rm. 7W444, Bethesda, MD 20892, 240-276-6340, 
grayp@mail.nih.gov.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: September 26, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-23961 Filed 10-1-13; 8:45 am]
BILLING CODE 4140-01-P